Allergen immunotherapy

PreclinicalBiologic

RRoxall Medicina España S.A

Allergen immunotherapy is one of 53 biologic programs targeting Rhinitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RhinitisActive, not recruiting

Allergic RhinitisActive, not recruiting

RhinitisPreclinical

Active, not recruiting

Allergic RhinitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Sudafed

KKenvue Brands

Phase 3

3 3

Flovent

PParatek Pharmaceuticals Inc

Phase 3

2 4

Rayos

RRoxane Laboratories

Phase 3

1 5

Kenalog

BBassett Healthcare

Phase 3

1 6

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 7

Active Comparator

Moderna

Phase 3

1 8

Allegra-D

Pfizer

Phase 3

3 9

Asmanex

Ismigen

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis2 trials

The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

Completed·RRohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.··NCT01318954·17 enrolled

Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma

Completed·RRoxall Medicina España S.A··NCT03821077·122 enrolled

Rhinitis1 trial

Corn Occupational Rhinitis SCIT Efficacy Study

Unknown status·UUnited Allergy Services·N/A·NCT02949050·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Allergen immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allergen immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allergen immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roxall Medicina España S.A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: RRoxall Medicina España S.A

Allergen immunotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis2 trials

Rhinitis1 trial

References

Drug Info

Quick Facts

Related News